Zavzpret (zavegepant)
Research Synopsis
Zavzpret (zavegepant)
Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonists.
London, UK
2 hours ago
1 Received
- Researchers found that CGRP receptor antagonists like Zavegepant are effective for treating migraines and have been tested in a Phase 2/3 trial with success using intranasal delivery.
- Zavegepant has a very low oral bioavailability in rats, prompting researchers to explore new compounds to improve this aspect.
- They developed a new compound (21) that maintains good binding affinity to the CGRP receptor and significantly enhances oral bioavailability compared to Zavegepant.
$100 - $150
Hourly Rate
Real world considerations for newly approved CGRP receptor antagonists in migraine care.
London, UK
2 hours ago
1 Received
- - Migraine is the top cause of disability for people under 50, with CGRP (calcitonin-gene related peptide) being essential in understanding its phases and treating it, leading to new medication breakthroughs known as gepants.
- - The review discusses the development of CGRP antagonists, from early C-terminus truncated versions to the latest gepants like Zavegepant, which represents advancements in migraine treatment.
- - Expert insights highlight the importance of exploring various signaling pathways involved in migraine, including the need for long-term data on gepants post-market to ensure their effectiveness and safety.
$100 - $150
Hourly Rate
Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review.
London, UK
2 hours ago
1 Received
- The objective of the study was to review small molecule CGRP receptor antagonists, specifically atogepant, rimegepant, and zavegepant, for preventing migraines, focusing on their chemistry, effectiveness, safety, and tolerability.
- A thorough search of studies revealed 599 results, from which 10 studies and 16 clinical trials were included, showing that atogepant and rimegepant significantly reduced migraine days and improved quality of life, with safety profiles similar to placebo.
- The conclusion highlighted that atogepant and rimegepant are effective for preventing migraines in adults, but more long-term safety studies and comparisons with existing treatments are necessary.
$100 - $150
Hourly Rate
Comparing the Liver Safety Profiles of 4 Next-Generation CGRP Receptor Antagonists to the Hepatotoxic CGRP Inhibitor Telcagepant Using Quantitative Systems Toxicology Modeling.
London, UK
2 hours ago
1 Received
- Calcitonin gene-related peptide (CGRP) signaling inhibitors can effectively treat migraines, but the first-generation drug telcagepant was withdrawn due to liver toxicity concerns.
- Four next-generation CGRP receptor antagonists (rimegepant, zavegepant, atogepant, and ubrogepant) showed promise in testing, but their safety needed validation compared to telcagepant.
- The DILIsym v6A model successfully predicted that the next-generation drugs would be safer for the liver, a prediction confirmed by subsequent clinical trials, leading to FDA approvals without hepatotoxicity warnings.
$100 - $150
Hourly Rate
A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine.
London, UK
2 hours ago
1 Received
- - Gepants are new small molecules that specifically target CGRP, showing promise as both preventive and abortive treatments for migraines and are currently undergoing further clinical development.
- - A systematic review was conducted to evaluate existing trials on gepants, while discussing their efficacy and safety compared to current migraine treatments and summarizing ongoing research.
- - There's still debate over the effectiveness and safety of targeting CGRP pathways directly in the brain versus indirectly from the nervous system, but gepants could be beneficial for patients unresponsive to traditional treatments, potentially offering new options for migraine management.
$100 - $150
Hourly Rate
A Comprehensive Review of Zavegepant as Abortive Treatment for Migraine.
London, UK
2 hours ago
1 Received
- Migraine headaches are common and complex, causing severe unilateral pain often linked with sensitivity to light and sound, significantly affecting daily life and leading to high emergency room visits and economic costs.
- Risk factors for migraines include genetics, gender, socioeconomics, and specific triggers such as stress, certain foods, and changes in sleep patterns.
- Treatment options involve abortive medications like triptans and new alternatives like Zavegepant, focusing on blocking key pain-related pathways in the brain.
$100 - $150
Hourly Rate
Gepants - a long way to cure: a narrative review.
London, UK
2 hours ago
1 Received
- - Calcitonin gene-related peptide (CGRP) is a key vasodilator in the brain, and new therapies targeting it, like monoclonal antibodies and gepants, are now available for treating migraines.
- - Monoclonal antibodies have shown high efficacy and tolerability in clinical trials, while gepants have demonstrated effectiveness for acute and preventive migraine treatment with varying results.
- - Ongoing research aims to better understand gepant safety and efficacy, particularly in combination with monoclonal antibodies, as well as their potential use for other conditions and in real-life clinical settings.
$100 - $150
Hourly Rate
Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial.
London, UK
2 hours ago
1 Received
- The study evaluated the effectiveness and safety of zavegepant nasal spray for treating migraines, focusing on its ability to provide quick pain relief and reduce bothersome symptoms.
- In a Phase 2/3 clinical trial involving 1,588 participants, the 10 mg and 20 mg doses of zavegepant significantly outperformed the placebo in achieving pain freedom and alleviating bothersome symptoms two hours after administration.
- Common side effects included dysgeusia (altered taste), occurring more frequently with zavegepant compared to the placebo, although the lower 5 mg dose did not show significant results.
$100 - $150
Hourly Rate
Focus on zavegepant: the first intranasal third-generation gepant.
London, UK
2 hours ago
1 Received
- - Migraine is a major cause of disability for people under 50, worsened by the effects of a protein called CGRP, leading to chronic migraine issues.
- - New treatments called gepants, which block the CGRP receptor, have evolved from older, possibly harmful drugs to safer options like oral rimegepant and ubrogepant, and the recently approved intranasal zavegepant.
- - The study aims to review the development of zavegepant and explore its potential in treating migraines, while also noting the need for more real-world data on the safety and effectiveness of these newer treatments.
$100 - $150
Hourly Rate
Gepants for Acute and Preventive Migraine Treatment: A Narrative Review.
London, UK
2 hours ago
1 Received
- Calcitonin gene-related peptide (CGRP) antagonists are medications used to prevent migraines, divided into monoclonal antibodies and gepants (small non-peptide molecules).
- The newer generation of gepants, including rimegepant, ubrogepant, and zavegepant, showed effectiveness in clinical trials for treating migraines without increasing mortality risks.
- Further research is needed to evaluate long-term side effects, particularly in elderly populations, and to monitor safety while comparing these treatments to older migraine medications like triptans.
$100 - $150
Hourly Rate
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.
London, UK
2 hours ago
1 Received
- Intranasal formulations, like zavegepant, offer an alternative treatment for migraine sufferers who can't tolerate oral medications due to side effects like nausea.
- This phase 3 trial involved 1978 adults with moderate to severe migraines, randomly assigning them to receive zavegepant nasal spray or a placebo and assessing outcomes like pain relief and bothersome symptoms after 2 hours.
- The study, conducted at 90 medical centers in the USA, aimed to evaluate the effectiveness, safety, and tolerability of zavegepant compared to placebo for acute migraine treatment.
$100 - $150
Hourly Rate
Zavegepant for the acute treatment of migraine: look before leaping.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
The pharmacotherapeutic management of episodic and chronic migraine with gepants.
London, UK
2 hours ago
1 Received
- Gepants are a new type of medication (non-peptide CGRP receptor antagonists) showing promise for treating both acute and chronic migraines.
- Key gepants include ubrogepant (for acute treatment), atogepant (for prevention), rimegepant (for both), and zavegepant (intranasal).
- Current research is inconclusive on whether gepants will outperform existing migraine treatments like triptans and monoclonal antibodies, as more studies are needed to assess their effectiveness.
$100 - $150
Hourly Rate
Zavegepant: First Approval.
London, UK
2 hours ago
1 Received
- * In March 2023, it was approved in the USA as a nasal spray (ZAVZPRET™) for acute migraine treatment in adults, whether or not they experience aura.
- * Research and development for an oral form of zavegepant is in progress, with the article highlighting the key milestones that led to the nasal spray's approval.
$100 - $150
Hourly Rate
Drugs for migraine.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Nasal spray (Zavegepant) for migraines: a mini-review.
London, UK
2 hours ago
1 Received
- Neurological disorders like migraines are a major global health issue, prompting innovative research into new treatments like Zavegepant, a recently approved nasal spray for acute migraine relief.
- Zavegepant is a first-in-class CGRP receptor antagonist that has shown better efficacy and safety in recent trials compared to traditional oral triptans, which many patients find less effective and harder to tolerate.
- While Zavegepant presents advantages, such as ease of use during migraine attacks, more research is needed to fully understand its long-term effects and interactions with other medications.
$100 - $150
Hourly Rate
Safety and Efficacy of Zavegepant in Treating Migraine: A Systematic Review.
London, UK
2 hours ago
1 Received
- Drugs targeting the calcitonin gene-related peptide (CGRP) pathway represent a new approach for treating migraine, with Zavegepant being the first intranasal CGRP antagonist developed.
- A systematic review of six studies evaluated Zavegepant's safety, efficacy, pharmacokinetics, and tolerability, focusing primarily on two randomized control trials with consistent results.
- Findings suggest that Zavegepant is an effective and well-tolerated treatment option for episodic migraines, demonstrating positive outcomes across various parameters, including adverse events and pain relief.
$100 - $150
Hourly Rate
Zavegepant (Zavzpret) for acute treatment of migraine.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Correction to: Zavegepant: First Approval.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
New Nasal Spray for Migraine Headaches.
London, UK
2 hours ago
1 Received
- - Zavegepant (Zavzpret) is a nasal spray approved for treating acute migraines in adults, with or without aura, but it's not meant for prevention.
- - Common side effects include taste disorders, nausea, nasal discomfort, and vomiting, along with possible hypersensitivity reactions.
- - Patients should not use zavegepant alongside intranasal decongestants, as they can reduce the effectiveness by decreasing the drug's absorption.
$100 - $150
Hourly Rate